Date Time
$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments
Amaroq Therapeutics, a new biotech start-up spun out of the University of Otago, with one of the world’s most advanced programs in next-generation RNA therapy to target cancer has secured NZ$14m investment to accelerate development.
Dr Sarah Diermeier.
The study of long non-coding RNAs (lncRNAs), often referred to as “dark matter” of the genome, are molecules naturally present in cells. Acting as key cell regulators despite not coding for proteins they have become one of the hottest areas of research globally. The emergence of new sequencing technologies has provided the opportunity to research these molecules further with significant investments being made globally into companies focusing on this area.
It is absolutely personal : The determined teen who became a cancer researcher stuff.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stuff.co.nz Daily Mail and Mail on Sunday newspapers.
New Zealand has a proven record in generating science and innovation for healthcare solutions but breaking into global markets poses problems for Kiwi start-ups. Experienced investors can help new businesses navigate the pathways to international success .